



September 2, 2014

## Agile Therapeutics to Ring the NASDAQ Stock Market Closing Bell

PRINCETON, N.J., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Mr. Al Altomari, the Company's President and Chief Executive Officer will ring The NASDAQ Stock Market Closing Bell this afternoon in celebration of Agile's May 22, 2014 listing on The NASDAQ Global Market.

"The successful completion of our IPO was a significant milestone for the Company and we are honored to ring the NASDAQ closing bell to mark this occasion today," stated Al Altomari. "With the funds raised, we are well positioned to advance our development plans for our confirmatory Phase 3 clinical trial for Twirla™, a combination hormonal contraceptive patch based on our proprietary Skinfusion® transdermal technology."

A live webcast of the NASDAQ Closing Bell (starting from 3:45 p.m. Eastern time) will be available at: <http://www.nasdaq.com/about/marketsitetowervideo.aspx>.

### About Agile

Agile Therapeutics is a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate, Twirla, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability. For more information, please visit the company website at [www.agiletherapeutics.com](http://www.agiletherapeutics.com).

CONTACT: Mary Coleman (609) 683-1880

Source: Agile Therapeutics

News Provided by Acquire Media